Quantcast
Last updated on April 16, 2014 at 0:15 EDT

Latest Immunohistochemistry Stories

2008-12-10 08:30:00

- May help avoid incorrect Breast Cancer diagnosis and management TORONTO, Dec. 10 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced that it has filed a provisional patent application that describes a new simplified method of quantifying immunohistochemical staining of biomarkers. The provisional patent application was filed with the United States Patent and Trademark office. This application, based on PreMD's existing colour measurement...

2008-10-31 12:00:32

SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, and City of Hope Hospital presented today the results from a meta-analysis examining the use of immunohistochemistry (IHC) to determine the origin of metastatic cancer at the second annual ASCO-NCI-EORTC Meeting on Molecular Markers in Cancer in Hollywood, Fla. In the meta-analysis, published peer-reviewed studies of the accuracy of IHC were reviewed. Researchers from...

2008-10-31 09:00:28

SUNNYVALE, Calif., Oct. 31 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, will present three studies involving the gene expression based Pathwork(R) Tissue of Origin Test at the Association for Molecular Pathology (AMP) Annual Meeting. In a poster entitled, "Gene Expression Microarray-Based Diagnostic Test May Identify Primary Tumor Site in Patients with Carcinoma of Unknown Primary (CUP)," Fabiola Medeiros, MD, Assistant Professor of Laboratory...

2008-09-23 18:00:15

PHILADELPHIA, Sept. 23 /PRNewswire/ -- Researchers have demonstrated a new instrument that makes it possible to detect and quantify multiple clinically important proteins in a single tumor sample using conventional staining. Currently, pathologists usually need separate tissue slices for each protein they want to examine, making it impossible to see how molecules interact within individual cells. The new process is fast and automated - up to 180 tumors from different patients can be...

2008-09-16 09:00:53

Invitrogen, a provider of essential life science technologies for research, production and diagnostics, has signed an exclusive US distribution agreement with Biocare Medical, a provider of immunohistochemistry reagents, multiplex stains, and automated platforms for the anatomic pathology market, for the new Spot-Light Her2 CISH kit. The Spot-Light Her2 CISH kit has received FDA premarket approval in July 2008, as an aid in the assessment of breast cancer patients for whom trastuzumab...

2008-09-15 18:00:37

Invitrogen Corporation, (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, has signed an exclusive U.S. distribution agreement with Biocare Medical LLC, a leading provider of immunohistochemistry reagents, multiplex stains, and automated platforms for the anatomic pathology market, for the new SPOT-Light(R) HER2 CISH Kit. The kit received U.S. Food and Drug Administration premarket approval in July, (click here for release), as an aid in...

2008-09-03 09:00:07

GAITHERSBURG, Md., Sept. 3 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for development of human cancer diagnostics and...

2008-08-20 09:01:30

Sigma-Aldrich has announced the addition of over 2,000 antibodies to its line of Prestige antibodies. These antibodies are developed by the Human Proteome Resource and are commercially available through an exclusive partnership with Sigma-Aldrich and Atlas Antibodies. The new antibodies were announced as the latest additions to the Human Protein Atlas portal. Initially consisting of 1,800 antibodies, the portfolio has grown to over 3,800 antibodies directed against 3,600 genes. The goal...

2008-08-19 18:00:43

ST. LOUIS, Aug. 19 /PRNewswire-FirstCall/ -- Sigma-Aldrich today announced the addition of over 2,000 antibodies to its line of Prestige Antibodies(TM). These antibodies are developed by the Human Proteome Resource and are commercially available through an exclusive partnership with Sigma-Aldrich and Atlas Antibodies. As part of a keynote HUPO 2008 Conference lecture given by Mathias Uhlen, Professor of Microbiology, Royal Institute of Technology (KTH) in Stockholm, Sweden, the new...

2008-07-31 09:00:28

SUNNYVALE, Calif., July 31 /PRNewswire/ -- Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Pathwork(R) Tissue of Origin Test for use in determining the origin of uncertain tumors. The test analyzes a tumor's gene expression pattern to help pinpoint the source of hard-to-identify tumors and is the first test of its kind to receive FDA clearance. Up to an estimated 200,000 newly...